tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Incyte initiated with an Overweight at Barclays

Barclays initiated coverage of Incyte (INCY) with an Overweight rating and $90 price target The firm sees “value-inflecting” data readouts for the company in the second half of 2025 and 2026. It believes the pivotal data for tafasitamab in diffuse large B-cell lymphoma and the Phase 2 data for povorcitinib in chronic spontaneous urticaria patients as providing the next legs of growth for Incyte.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1